Patents by Inventor Galen Paul Shearn-Nance

Galen Paul Shearn-Nance has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20240025923
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 25, 2024
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230416227
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 28, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Maoqun Tian, Salman Jabri, Galen Paul Shearn-Nance, Rongze Kuang, Zhiqiang Zhao, Zhicai Wu
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230348428
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. HICKS, Rongze Kuang, Christopher J. Sinz, Matthew J. Lombardo, Jovan Alexander Lopez, Rohan Rajiv Merchant, Phillip Patrick Sharp, Zhicai Wu, Zhiqiang Zhao, Alan C. Cheng, Song Yang, Jianming Bao, Maoqun Tian, Galen Paul Shearn-Nance
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20230286958
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 14, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Salman Jabri, Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Brandon M. Taoka, Maoqun Tian, Galen Paul Shearn-Nance, Rongze Kuang, Matthew J. Lombardo, Zhicai Wu, Zhiqiang Zhao
  • Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
    Patent number: 11739101
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: August 29, 2023
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF
    Publication number: 20210355140
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 18, 2021
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell